PDF(Pubmed)
Abstract：
BACKGROUND: Early knee osteoarthritis (OA) treatment is multimodal, with physical therapy and pharmacotherapy commonly used. Although popular, oral supplements like glucosamine and diacerein have not been reported to have high efficacy. Undenatured collagen type II (UC-II) has been introduced for therapy in early OA; it helps in cartilage repair and preservation. The present review was done to ascertain its efficacy in pain relief and knee function.
METHODS: A systematic literature search was performed on MEDLINE (PubMed), Embase, Scopus, and Cochrane Library for published literature; studies comparing the outcome of UC-II supplementation with placebo/control in adult humans with early knee OA were included. The outcomes evaluated were VAS Score, quality of life - Western Ontario and McMaster Universities (WOMAC-score), Knee function, Knee range of motion, and any complications during the course of treatment.
RESULTS: A total of 293 results were obtained after a primary search; 8 randomized control trials (RCT) were finally included. A total of 243 patients received UC-II supplementation (91 men and 152 women). The overall mean age range for the intervention group was 53.5±0.99 to 68.7±5.3 years across all included studies, and the mean follow-up duration was 3 to 6 months. Outcome measures like WOMAC and VAS scores showed better outcomes with UC-II in comparison to placebo. Walking measurements improved significantly from the baseline, reflected in improved timed up-and-go and 6-minute walk tests (6MWT). The overall complications were similar to other supplements.
CONCLUSIONS: With limited literature, UC-II has shown promise as a potent supplement in early knee OA with good pain relief and improved function. However, further large-scale studies are needed to substantiate these findings.
METHODS: A systematic literature search was performed on MEDLINE (PubMed), Embase, Scopus, and Cochrane Library for published literature; studies comparing the outcome of UC-II supplementation with placebo/control in adult humans with early knee OA were included. The outcomes evaluated were VAS Score, quality of life - Western Ontario and McMaster Universities (WOMAC-score), Knee function, Knee range of motion, and any complications during the course of treatment.
RESULTS: A total of 293 results were obtained after a primary search; 8 randomized control trials (RCT) were finally included. A total of 243 patients received UC-II supplementation (91 men and 152 women). The overall mean age range for the intervention group was 53.5±0.99 to 68.7±5.3 years across all included studies, and the mean follow-up duration was 3 to 6 months. Outcome measures like WOMAC and VAS scores showed better outcomes with UC-II in comparison to placebo. Walking measurements improved significantly from the baseline, reflected in improved timed up-and-go and 6-minute walk tests (6MWT). The overall complications were similar to other supplements.
CONCLUSIONS: With limited literature, UC-II has shown promise as a potent supplement in early knee OA with good pain relief and improved function. However, further large-scale studies are needed to substantiate these findings.
摘要：
背景：早期膝骨性关节炎（OA）治疗是多模式的，通常使用的物理治疗和药物治疗。虽然受欢迎，诸如葡糖胺和双醋瑞因之类的口服补充剂尚未被报道具有高功效。未变性的II型胶原蛋白（UC-II）已被引入用于早期OA的治疗；它有助于软骨修复和保存。本综述旨在确定其在疼痛缓解和膝关节功能方面的功效。
方法：在MEDLINE（PubMed）上进行了系统的文献检索，Embase,Scopus,和Cochrane图书馆的已发表文献;包括比较UC-II补充与安慰剂/对照在成人早期膝关节OA中的结果的研究。评估的结果是VAS评分，生活质量-西安大略省和麦克马斯特大学（WOMAC分数），膝关节功能,膝关节运动范围,以及治疗过程中的任何并发症。
结果：经过初步搜索，共获得293个结果；最终纳入8个随机对照试验（RCT）。共有243名患者接受UC-II补充（男性91名，女性152名）。在所有纳入研究中，干预组的总体平均年龄为53.5±0.99至68.7±5.3岁，平均随访时间为3~6个月。与安慰剂相比，UC-II的WOMAC和VAS评分等结果指标显示出更好的结果。步行测量值从基线显着改善，反映在改进的定时上行和上行和6分钟步行测试（6MWT）。总体并发症与其他补充剂相似。
结论：由于文献有限，UC-II已显示出有望作为早期膝关节OA的有效补充，具有良好的疼痛缓解和改善的功能。然而,需要进一步的大规模研究来证实这些发现.
方法：在MEDLINE（PubMed）上进行了系统的文献检索，Embase,Scopus,和Cochrane图书馆的已发表文献;包括比较UC-II补充与安慰剂/对照在成人早期膝关节OA中的结果的研究。评估的结果是VAS评分，生活质量-西安大略省和麦克马斯特大学（WOMAC分数），膝关节功能,膝关节运动范围,以及治疗过程中的任何并发症。
结果：经过初步搜索，共获得293个结果；最终纳入8个随机对照试验（RCT）。共有243名患者接受UC-II补充（男性91名，女性152名）。在所有纳入研究中，干预组的总体平均年龄为53.5±0.99至68.7±5.3岁，平均随访时间为3~6个月。与安慰剂相比，UC-II的WOMAC和VAS评分等结果指标显示出更好的结果。步行测量值从基线显着改善，反映在改进的定时上行和上行和6分钟步行测试（6MWT）。总体并发症与其他补充剂相似。
结论：由于文献有限，UC-II已显示出有望作为早期膝关节OA的有效补充，具有良好的疼痛缓解和改善的功能。然而,需要进一步的大规模研究来证实这些发现.
